Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for GBLX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
December 31, 2024 -5.88M
September 30, 2024 -5.780M
June 30, 2024 -5.589M
March 31, 2024 -5.314M
December 31, 2023 -4.847M
September 30, 2023 -4.693M
June 30, 2023 -4.680M
March 31, 2023 -4.407M
December 31, 2022 -1.612M
September 30, 2022 -1.193M
June 30, 2022 -2.166M
March 31, 2022 -1.783M
December 31, 2021 1.803M
September 30, 2021 -2.538M
June 30, 2021 -2.030M
March 31, 2021 -1.474M
December 31, 2020 -2.496M
September 30, 2020 -2.350M
June 30, 2020 -1.649M
March 31, 2020 -0.0885M
December 31, 2019 8.302M
September 30, 2019 5.288M
June 30, 2019 6.887M
March 31, 2019 8.300M
December 31, 2018 10.33M
Date Value
September 30, 2018 12.88M
June 30, 2018 13.39M
March 31, 2018 12.75M
December 31, 2017 8.476M
September 30, 2017 7.535M
June 30, 2017 7.316M
March 31, 2017 8.327M
December 31, 2016 3.584M
September 30, 2016 2.073M
June 30, 2016 -0.6159M
March 31, 2016 -1.896M
December 31, 2015 -1.081M
September 30, 2015 -0.4015M
June 30, 2015 -1.336M
March 31, 2015 0.4973M
December 31, 2014 1.148M
September 30, 2014 2.018M
June 30, 2014 2.696M
March 31, 2014 -1.013M
December 31, 2013 -1.141M
September 30, 2013 -0.9579M
June 30, 2013 -1.232M
March 31, 2013 -1.190M
December 31, 2012 -0.8324M
September 30, 2012 -0.9223M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Cocrystal Pharma, Inc. 1.044M
CNBX Pharmaceuticals, Inc. -2.660M
Arvinas, Inc. 562.20M
Fulcrum Therapeutics, Inc. 310.70M
Definium Therapeutics, Inc. 918.68M